Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study

Background Rituximab (RTX) is effective in maintaining remission in patients with nephrotic syndrome (NS), but a standard protocol of RTX administration has not been established.